Year |
Citation |
Score |
2023 |
Lee JC, Brien HJ, Walton BL, Eidman ZM, Toda S, Lim WA, Brunger JM. Instructional materials that control cellular activity through synthetic Notch receptors. Biomaterials. 297: 122099. PMID 37023529 DOI: 10.1016/j.biomaterials.2023.122099 |
0.409 |
|
2021 |
Choi YR, Collins KH, Springer LE, Pferdehirt L, Ross AK, Wu CL, Moutos FT, Harasymowicz NS, Brunger JM, Pham CTN, Guilak F. A genome-engineered bioartificial implant for autoregulated anticytokine drug delivery. Science Advances. 7: eabj1414. PMID 34516920 DOI: 10.1126/sciadv.abj1414 |
0.712 |
|
2020 |
Huynh NP, Gloss CC, Lorentz J, Tang R, Brunger JM, McAlinden A, Zhang B, Guilak F. Long non-coding RNA enhances chondrogenesis via suppression of interferon type II signaling pathway. Elife. 9. PMID 32202492 DOI: 10.7554/Elife.49558 |
0.549 |
|
2019 |
Pferdehirt L, Ross AK, Brunger JM, Guilak F. A Synthetic Gene Circuit for Self-Regulating Delivery of Biologic Drugs in Engineered Tissues. Tissue Engineering. Part A. PMID 30968743 DOI: 10.1089/Ten.Tea.2019.0027 |
0.662 |
|
2018 |
Huynh NPT, Brunger JM, Gloss CC, Moutos FT, Gersbach CA, Guilak F. Genetic Engineering of Mesenchymal Stem Cells for Differential Matrix Deposition on 3DWoven Scaffold. Tissue Engineering. Part A. PMID 29756533 DOI: 10.1089/Ten.Tea.2017.0510 |
0.779 |
|
2017 |
Adkar SS, Brunger JM, Willard VP, Wu CL, Gersbach CA, Guilak F. Genome Engineering for Personalized Arthritis Therapeutics. Trends in Molecular Medicine. PMID 28887050 DOI: 10.1016/J.Molmed.2017.08.002 |
0.755 |
|
2017 |
Brunger JM, Zutshi A, Willard VP, Gersbach CA, Guilak F. Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs. Stem Cell Reports. PMID 28457885 DOI: 10.1016/J.Stemcr.2017.03.022 |
0.793 |
|
2017 |
Farhang N, Brunger JM, Stover JD, Thakore PI, Lawrence B, Guilak F, Gersbach CA, Setton LA, Bowles RD. CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments. Tissue Engineering. Part A. PMID 28095751 DOI: 10.1089/Ten.Tea.2016.0441 |
0.595 |
|
2016 |
Brunger JM, Zutshi A, Willard VP, Gersbach CA, Guilak F. CRISPR/Cas9 editing of induced pluripotent stem cells for engineering inflammation-resistant tissues. Arthritis & Rheumatology (Hoboken, N.J.). PMID 27813286 DOI: 10.1002/Art.39982 |
0.812 |
|
2016 |
Glass KA, Rowland CR, Ettyreddy AR, Brunger JM, Huynh NP, Gersbach CA, Guilak F. 502. Biomaterial-Mediated Lentiviral Delivery of Anti-Inflammatory Genes in Cartilage-Derived Matrix Hemispheres Molecular Therapy. 24: S199-S200. DOI: 10.1016/S1525-0016(16)33311-1 |
0.754 |
|
2016 |
Adkar SS, Willard VP, Brunger JM, Shiao KT, Gersbach CA, Guilak F. 318. Targeted Genome Editing of Human Induced Pluripotent Stem Cells Using CRISPR/CAS9 to Generate a Knock-in Type II Collagen Reporter for the Purification of Chondrogenic Cells Molecular Therapy. 24: S128. DOI: 10.1016/S1525-0016(16)33127-6 |
0.771 |
|
2015 |
Diekman BO, Thakore PI, O'Connor SK, Willard VP, Brunger JM, Christoforou N, Leong KW, Gersbach CA, Guilak F. Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells. Tissue Engineering. Part A. 21: 1261-74. PMID 25517798 DOI: 10.1089/Ten.Tea.2014.0240 |
0.777 |
|
2015 |
Brunger JM, Zutshi A, Willard VP, Gersbach CA, Guilak F. 504. Targeted Genome Engineering of Induced Pluripotent Stem Cells To Produce Auto-Regulated Inflammation Resistance for Musculoskeletal Regenerative Medicine Molecular Therapy. 23: S201-S202. DOI: 10.1016/S1525-0016(16)34113-2 |
0.803 |
|
2014 |
Glass KA, Link JM, Brunger JM, Moutos FT, Gersbach CA, Guilak F. Tissue-engineered cartilage with inducible and tunable immunomodulatory properties. Biomaterials. 35: 5921-31. PMID 24767790 DOI: 10.1016/J.Biomaterials.2014.03.073 |
0.782 |
|
2014 |
Brunger JM, Huynh NP, Guenther CM, Perez-Pinera P, Moutos FT, Sanchez-Adams J, Gersbach CA, Guilak F. Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage. Proceedings of the National Academy of Sciences of the United States of America. 111: E798-806. PMID 24550481 DOI: 10.1073/Pnas.1321744111 |
0.778 |
|
2013 |
Francisco AT, Mancino RJ, Bowles RD, Brunger JM, Tainter DM, Chen YT, Richardson WJ, Guilak F, Setton LA. Injectable laminin-functionalized hydrogel for nucleus pulposus regeneration. Biomaterials. 34: 7381-8. PMID 23849345 DOI: 10.1016/J.Biomaterials.2013.06.038 |
0.47 |
|
2013 |
Perez-Pinera P, Ousterout DG, Brunger JM, Farin AM, Glass KA, Guilak F, Crawford GE, Hartemink AJ, Gersbach CA. Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nature Methods. 10: 239-42. PMID 23377379 DOI: 10.1038/Nmeth.2361 |
0.736 |
|
2013 |
Glass K, Brunger J, Gersbach C, Guilak F. Tunable expression of IL-1Ra in genetically modified mesenchymal stem cells for cartilage tissue engineering Osteoarthritis and Cartilage. 21: S282-S283. DOI: 10.1016/J.Joca.2013.02.591 |
0.815 |
|
2013 |
Francisco A, Mancino R, Brunger J, Bowles R, Guilak F, Setton L. Injectable laminin-functionalized hydrogel for cell delivery to the intervertebral disc Osteoarthritis and Cartilage. 21: S278-S279. DOI: 10.1016/J.Joca.2013.02.585 |
0.455 |
|
2010 |
Abrahamsson CK, Yang F, Park H, Brunger JM, Valonen PK, Langer R, Welter JF, Caplan AI, Guilak F, Freed LE. Chondrogenesis and mineralization during in vitro culture of human mesenchymal stem cells on three-dimensional woven scaffolds. Tissue Engineering. Part A. 16: 3709-18. PMID 20673022 DOI: 10.1089/Ten.Tea.2010.0190 |
0.536 |
|
Show low-probability matches. |